MicroRNAs circulate around Alzheimer's disease by unknown
Millions of people suff er from Alzheimer’s disease (AD) 
every year, and the number of affl  icted individuals is 
expected to increase drastically worldwide as the elderly 
population expands. AD is the most common form of 
dementia and often onsets after age  65. Currently, 
analysis of cerebrospinal ﬂ uid proteins, such as Aβ42, tau 
and p-tau, can only truly indicate a confi rmation of AD 
diagnosis based on a clinical suspicion, or as a diff erential 
diagnosis from other neurological diseases that cause 
dementia-like symptoms. Th us, the search to fi nd early-
stage biomarkers of this disease is of utmost importance.
Recently, blood-based biomarkers for AD have been 
proposed as attractive diagnostic tools, as they are non-
invasive, highly specifi c and sensitive, and can be isolated 
with standard laboratory equipment. A number of 
studies have identifi ed such blood-based AD biomarkers 
and demonstrated promising results. For example, one 
study reported a panel of three blood markers (cortisol, 
von Willebrand factor and oxidized low-density lipo-
protein antibodies) that distinguished AD patients from 
healthy controls [1], while another group identifi ed 18 
proteins in blood plasma that could diff erentiate AD 
patients from controls with clinically relevant accuracy, 
sensitivity and specifi city [2].
Circulating microRNAs enter the diagnostics scene
In addition to measuring protein levels in circulation, 
microRNAs (miRNAs) have also been shown to be 
eff ective blood-based biomarkers for a wide array of 
diseases. Th e fi eld of circulating miRNAs has been rapidly 
gaining momentum over approximately the last 5 years, 
beginning with the discovery that miRNAs themselves 
can be easily detected and quantifi ed in multiple body 
ﬂ uids, including blood. Th ese circulating miRNAs are 
resistant to RNases and are in fact very stable in an 
extracellular environment, in which they can be 
packaged in microvesicles, exosomes or apop totic 
bodies. Circulating miRNAs can also be found in 
ultrastable protein complexes with Argonaute2, which 
is the key factor involved in miRNA-mediated repres-
sion of target genes [3]. It appears that these miRNAs 
found in exosomes or in protein complexes may be the 
remnants of dead cells that have already been cleared. 
Circulating miRNAs have been profi led from peripheral 
blood mononuclear cells (PBMCs), plasma, serum and 
whole blood, although there has been some disagreement 
as to whether there are distinct or reproducible popu-
lations of miRNAs detected from each of these sources.
Nevertheless, quantifi cation of miRNAs found in blood 
samples has yielded fruitful results for potential early-
stage diagnosis of numerous cancers and other patho-
logies, making them an attractive new class of disease 
biomarkers. In a collaborative study, miRNome analysis 
of 454  blood samples from individuals with diff erent 
cancers or other diseases yielded strongly dysregulated 
miRNA profi les for all tested diseases. Further, there 
appeared to be signifi cant correlations between these 
dysregulated miRNAs and the genomic location of 
disease-associated genetic variants [4].
A novel miRNA biomarker signature of Alzheimer’s 
disease
Profi ling of circulating miRNAs has now been identifi ed 
as a useful biomarker tool for AD as well. In this issue of 
Genome Biology, Petra Leidinger and colleagues report 
their identifi cation of a novel miRNA signature for 
detecting AD from blood samples [5]. Th ey performed 
high-throughput Illumina sequencing of all human 
miRNAs from whole-blood samples of 48  patients 
affl  icted with AD and 22  age-matched healthy controls, 
and saw 82  upregulated and 58  downregulated mature 
miRNAs in AD patients. It appeared that at least some of 
these 140 dysregulated miRNAs cluster together within a 
localized genome region, implicating a possible shared 
regulatory mechanism of miRNA expression.
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The most upregulated and downregulated miRNAs had 
already been described in relation to various diseases and 
thus did not appear to be specific for AD. To differentiate 
miRNA expression in AD and control samples, the 
researchers used standard machine learning to yield a 
250-miRNA signature with high accuracy, sensitivity and 
specificity. However, as many of these miRNAs were 
strongly correlative with each other, the researchers 
selected a smaller panel of miRNAs with limited cross-
correlation that were also dysregulated in AD patients 
based on the Illumina sequencing results, but not in 
many other diseases published in the literature.
The next-generation sequencing also detected lowly 
expressed novel miRNA candidates, which the authors 
termed brain-miRs. They identified 15 brain-miRs, all of 
which were upregulated in AD compared with healthy 
controls. To represent this new class of miRNAs, the 
researchers selected two brain-miRs to include in their 
smaller panel. The 12-miRNA panel consists of seven 
upregulated miRNAs (brain-miR-112, brain-miR-161, 
hsa-let-7d-3p, hsa-miR-5010-3p, hsa-miR-26a-5p, hsa-
miR-1285-5p and hsa-miR-151a-3p) and five down regu-
lated miRNAs (hsa-miR-103a-3p, hsa-miR-107, hsa-miR-
532-5p, hsa-miR-26b-5p and hsa-let-7f-5p). While this 
miRNA signature represents a unique group of miRNAs 
that has not been identified thus far in its relationship to 
AD, two of these miRNAs (miR-103 and miR-107) have 
previously been implicated in the disease, thus increasing 
confidence in the selection process of this miRNA 
signature. In a recent study, miR-103 and miR-107 were 
both shown to reduce expression of their target, 
ADAM10, which controls the processing of amyloid 
precursor protein and the formation of amyloid plaques 
[6].
Distinguishing Alzheimer’s patients from controls 
using the miRNA panel
To validate these differentially expressed miRNAs in a 
larger cohort, the researchers performed quantitative RT-
PCR (qRT-PCR) analysis of 12  miRNAs in 202 samples 
from AD patients, healthy controls, and patients afflicted 
with other neurodegenerative diseases or psychiatric 
disorders. Ten out of the 12 miRNAs were dysregulated 
in the same direction when comparing next-generation 
sequencing and qRT-PCR results, showing that the 
findings from the screen and validation cohort were 
concordant. Support vector machine classification on the 
qRT-PCR data reached 93.3% accuracy, as well as high 
sensitivity and specificity in distinguishing between AD 
patients and controls.
The expression profile of this 12-miRNA panel was also 
able to separate AD patients and patients with other 
neuro logical disorders, albeit with lower accuracy. As 
patients with other neurodegenerative diseases or 
psychi atric disorders can sometimes exhibit AD-related 
symptoms, the authors were curious to see if these 
patients showed comparable dysregulation in the 
expression of the miRNA signature. Schizophrenia 
patients showed a pattern most similar to AD, in which 
there were six upregulated and six downregulated 
miRNAs. Patients with other disorders also showed 
either significant overall upregulation or downregulation 
of all the 12 miRNAs. Lastly, the authors noted that the 
AD miRNA signature can distinguish other neurological 
diseases from the control group using support vector 
machine classification; surprisingly, the group of psycho-
logical disorders was more accurate than AD or the 
group of neurodegenerative diseases in separation from 
the control group.
Insights into potential miRNA targets
Leidinger et al. have shown that identifying dysregulation 
of miRNA expression in peripheral blood can be a useful 
biomarker for diagnosis of AD and other neurological 
disorders [5]. Many studies have investigated the role of 
miRNAs in neurodegenerative diseases; until this work 
from Leidinger and colleagues, however, very few reports 
have analyzed blood-borne miRNA expression profiles in 
AD patients. Schipper et al. [7] profiled miRNA expres-
sion in PBMCs of 16  AD patients and 16  controls, in 
order to identify miRNAs that may be responsible for 
targeting mRNAs also shown to be downregulated in AD 
patients. However, the study found only a very slight 
increase in expression of nine miRNAs in these patients 
compared with controls.
The identification of targets of significantly dysregu-
lated miRNAs in AD patients remains an important 
factor for understanding the potential regulatory mecha-
nisms of miRNAs in this disease. Leidinger et al. 
identified 2,354 mRNAs predicted to be targeted by the 
10  known miRNAs in the 12-miRNA signature. The 
authors performed over-representation analysis of these 
predicted targets and found an enrichment of miRNA 
targets in Gene Ontology categories of neuron projection 
development, morphogenesis and other related cate gor-
ies. In fact, many of these predicted targets have already 
been related to AD or other neurological diseases, 
including DRD1 (dopamine receptor D1), BDNF (brain-
derived neurotrophic factor), IGF1R (insulin growth 
factor  1 receptor) and DISC1 (disrupted in schizo phre-
nia  1). DISC1 was also a predicted target of a novel 
miRNA (brain-miR-112) identified from high-throughput 
sequencing.
It should be noted that these genes are only predicted 
to be targeted by the miRNA panel using bioinformatics; 
however, a recent study has shed light on analysis of 
miRNA-mRNA relationships in AD patients. In an effort 
to simultaneously examine miRNA and mRNA 
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expression in AD patients, Nunez-Iglesias et al. [8] have 
provided the first joint profile analysis of miRNAs and 
mRNAs in brain cortex from AD and age-matched 
controls. By identifying numerous miRNA-mRNA pairs 
that are altered in AD versus control patients, the data 
provide a unique resource for studying the relationships 
between miRNA and mRNA expression in normal and 
AD brains [8].
Future directions
Leidinger and colleagues acknowledge that, while this 
12-miRNA signature demonstrates impressive accuracy 
in identifying blood samples from AD patients, this may 
still not be the most effective diagnostic approach. The 
authors conclude that a combination of AD-specific 
miRNA profiles, along with other standard diagnostic 
tools, may be the best method for diagnosing AD at early 
stages [5]. Additionally, any direct relationship between 
AD diagnosis from brain tissue samples or from blood 
samples remains to be validated, as tissue and blood 
samples from the same patients were not available for 
this study. It will be important to show in the future that 
miRNA profiling from blood or tissue samples will 
achieve the same AD diagnosis of a patient.
This study profiled miRNAs from whole blood; as 
mentioned earlier, there has been some debate over 
whether whole blood or isolated plasma or serum 
fractions should be utilized when performing blood-
based biomarker studies. Nevertheless, a serum profiling 
of AD patients was, in fact, the first study to show that 
profiling of circulating miRNAs can be a useful AD 
biomarker, by identifying four downregulated miRNAs in 
the serum of probable AD patients and risk factor models 
[9]. Future work could simultaneously compare miRNA 
profiles in serum, plasma and whole blood in AD patients 
and controls to identify the most consistent approach for 
circulating miRNA biomarker studies.
Leidinger and colleagues also used their miRNA 
signature to differentiate between blood samples from 
patients with mild cognitive impairment (MCI) versus 
healthy controls. A recent report has identified two 
miRNA classes that could also differentiate patients with 
MCI from controls [10]. Moreover, these miRNA bio-
markers successfully detected MCI in a majority of 
patients in an asymptomatic stage, 1 to 5 years before a 
clinical diagnosis [10]. The ability to identify MCI in 
patients could very well delay the onset of AD, as early 
stages of many neurodegenerative diseases, including 
development of AD, are associated with MCI.
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